You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華東醫藥(000963.SZ):英國Sinclair公司與瑞士Kylane公司達成股權投資和產品合作開發協議
格隆匯 10-15 19:38

格隆匯10月15日丨華東醫藥(000963.SZ)公佈,公司英國全資子公司Sinclair Pharma Limited(以下簡稱“Sinclair公司”)與瑞士先進醫美研發機構Kylane Laboratoires SA(以下簡稱“Kylane公司”)達成股權投資和產品合作開發協議:1)股權投資協議,Sinclair公司出資600萬歐元受讓Kylane公司現有股東持有的所有普通股,交易完成後Sinclair公司持有Kylane公司20%股權,成為其第三大股東;2)產品合作開發協議,Sinclair公司每年將向Kylane公司支付一定金額支持其研發活動,並有權以約定對價獲得Kylane公司在面部和身體填充劑領域兩款重點研發產品的IP(知識產權)及其全球權益。同時根據協議約定,Sinclair公司將擁有Kylane公司未來其他後續研發產品的優先談判權。

Kylane公司在玻尿酸領域深度佈局,技術領先且在研產品儲備豐富,管線涵蓋面部填充、身體塑形等多個創新型產品,核心專利佈局完善,符合全球玻尿酸和其他填充劑領域的主流佈局和發展趨勢,具有良好的市場前景。

通過此次股權投資以及產品開發合作,公司在提前鎖定Kylane公司現有兩款重點研發產品權益的基礎上,還擁有Kylane公司未來其他後續研發產品的優先談判權。本次交易將進一步豐富公司醫美產品管線,實現公司在面部和身體塑形應用產品的深度佈局,符合公司國際化發展及開拓全球醫美業務的戰略發展需要。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account